FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594133760> ?p ?o ?g. }

• W2594133760 endingPage "246" @default.
• W2594133760 startingPage "246" @default.
• W2594133760 abstract "Abstract Introduction: Daratumumab (DARA) is a human monoclonal IgG1κ CD38 antibody that functions through multifaceted mechanisms of action, including CDC, ADCC, ADCP, induction of apoptosis and immunomodulatory activity (Krejcik et al, Blood 2016;128:384-394). DARA was added to standard of care (SOC) regimens in two randomized, controlled, phase 3 trials in RRMM: POLLUX (DARA+lenalidomide/dexamethasone [DRd] vs lenalidomide/dexamethasone [Rd]) and CASTOR (DARA+bortezomib/dexamethasone [DVd] vs bortezomib/dexamethasone [Vd]). The addition of DARA to these regimens resulted in significant improvements in PFS (hazard ratio for PFS: 0.37 and 0.39 for POLLUX and CASTOR, respectively) and ORR (POLLUX: 93% DRd vs 76% Rd; CASTOR: 83% DVd vs 63% Vd) (Dimopoulos MA et al, N Engl J Med 2016; in press; Palumbo A et al, N Engl J Med 2016; in press). To determine the ability of DARA to drive deep clinical responses beyond complete response (CR), MRD was assessed in both POLLUX and CASTOR using next-generation sequencing (NGS) of B cell receptor (Ig). This is the first comprehensive and prospective study of MRD to date in randomized phase 3 clinical trials of RRMM patients and investigates the ability of DARA-containing regimens to drive deep responses in this challenging population. Methods: MRD was assessed in POLLUX (blinded to treatment group) at the time of suspected CR, and at 3 and 6 months post-suspected CR for patients who maintained this response. Similarly, in CASTOR, MRD was assessed for patients at the time of suspected CR (blinded to treatment group) and at 6 months and 12 months after first dose (at the end and 6 months after end of Vd background therapy, respectively). MRD was assessed on bone marrow aspirate samples prepared using Ficoll and evaluated by the ClonoSEQTM assay (Adaptive Biotechnologies, Seattle, WA, USA) at sensitivities of 0.01% (1 cancer cell per 10,000 nucleated cells or 10-4), 0.001% (10-5), and 0.0001% (10-6). The MRD negative rate per treatment arm was determined as the proportion of patients with negative MRD at any time point after the first dose and compared using the likelihood-ratio test. To allow for a stringent, unbiased evaluation of MRD in these studies, the entire intent-to-treat population was evaluated where patients were considered MRD positive if they had only MRD positive test result or had no MRD assessment. In POLLUX, 63% in DRd and 87% in Rd did not receive a MRD assessment, and for CASTOR, 76% in DVd and 87% in Vd were not assessed for MRD. Results: Median duration of follow-up was 13.5 months and 7.4 months in POLLUX and CASTOR, respectively. The addition of DARA to SOC regimens (Rd in POLLUX or Vd in CASTOR) resulted in significantly higher MRD negative rates at all three thresholds examined (10-4, 10-5, and 10-6; Table). Additionally, patients who achieved MRD negative status experienced fewer PFS events compared with MRD positive patients at a threshold of 10-5 (Figure). Among pts who achieved CR or better, the rate of MRD negativity was at least 3-fold higher across all sensitivity thresholds in the DARA + SOC treatment groups compared with SOC alone. In MRD positive patients, PFS was significantly longer in the DARA + SOC treatment groups compared with SOC alone treatment arms. Updated data from both studies will be presented at the annual meeting. Conclusion: These two studies represent the first randomized, controlled, prospective evaluation of MRD in the RRMM phase 3 clinical trial setting and demonstrate that DARA-containing therapies are able to drive patients to remarkably deep levels of clinical response. Regardless of the SOC component, DARA-containing regimens consistently demonstrated ≥3-fold increase in MRD negative rate compared with the control groups at all evaluated thresholds. Importantly, since patients who achieved MRD negative status demonstrated low PFS event rates, the deep clinical responses induced by DARA may lead to improved survival. Table MRD negative Rate Based on Threshold Used Table. MRD negative Rate Based on Threshold Used Figure Progression-free survival by MRD status in POLLUX and CASTOR Figure. Progression-free survival by MRD status in POLLUX and CASTOR Disclosures Avet-Loiseau: Celgene: Honoraria, Research Funding, Speakers Bureau; Amgen: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau; Janssen: Honoraria, Research Funding, Speakers Bureau. Casneuf:Janssen R&D, Beerse, Belgium: Employment; Johnson & Johnson: Equity Ownership. Chiu:Janssen: Employment. Moreau:Janssen: Honoraria, Speakers Bureau; Amgen: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria. Plesner:Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Khokhar:Janssen: Employment. Qi:Janssen: Employment. Schecter:Janssen: Employment, Equity Ownership. Carlton:Adaptive Biotechnologies: Employment, Equity Ownership. Qin:Janssen: Employment. Liu:Janssen: Employment; J&J: Equity Ownership; Merck: Equity Ownership. Wu:Janssen: Employment. Zhuang:Janssen: Employment. Ahmadi:Janssen: Employment. Sasser:J&J: Equity Ownership; Janssen: Employment. San-Miguel:Amgen: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Onyx: Membership on an entity's Board of Directors or advisory committees; Millennium: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees." @default.
• W2594133760 created "2017-03-16" @default.
• W2594133760 creator A5010388094 @default.
• W2594133760 creator A5011533368 @default.
• W2594133760 creator A5013519562 @default.
• W2594133760 creator A5014436946 @default.
• W2594133760 creator A5015733850 @default.
• W2594133760 creator A5015892119 @default.
• W2594133760 creator A5028707750 @default.
• W2594133760 creator A5029035458 @default.
• W2594133760 creator A5041987846 @default.
• W2594133760 creator A5049711954 @default.
• W2594133760 creator A5063422967 @default.
• W2594133760 creator A5064631593 @default.
• W2594133760 creator A5069449708 @default.
• W2594133760 creator A5077388722 @default.
• W2594133760 creator A5081769123 @default.
• W2594133760 creator A5084124427 @default.
• W2594133760 creator A5086005303 @default.
• W2594133760 creator A5086077649 @default.
• W2594133760 creator A5089163384 @default.
• W2594133760 date "2016-12-02" @default.
• W2594133760 modified "2023-10-18" @default.
• W2594133760 title "Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone" @default.
• W2594133760 doi "https://doi.org/10.1182/blood.v128.22.246.246" @default.
• W2594133760 hasPublicationYear "2016" @default.
• W2594133760 type Work @default.
• W2594133760 sameAs 2594133760 @default.
• W2594133760 citedByCount "28" @default.
• W2594133760 countsByYear W25941337602017 @default.
• W2594133760 countsByYear W25941337602018 @default.
• W2594133760 countsByYear W25941337602019 @default.
• W2594133760 countsByYear W25941337602020 @default.
• W2594133760 countsByYear W25941337602022 @default.
• W2594133760 countsByYear W25941337602023 @default.
• W2594133760 crossrefType "journal-article" @default.
• W2594133760 hasAuthorship W2594133760A5010388094 @default.
• W2594133760 hasAuthorship W2594133760A5011533368 @default.
• W2594133760 hasAuthorship W2594133760A5013519562 @default.
• W2594133760 hasAuthorship W2594133760A5014436946 @default.
• W2594133760 hasAuthorship W2594133760A5015733850 @default.
• W2594133760 hasAuthorship W2594133760A5015892119 @default.
• W2594133760 hasAuthorship W2594133760A5028707750 @default.
• W2594133760 hasAuthorship W2594133760A5029035458 @default.
• W2594133760 hasAuthorship W2594133760A5041987846 @default.
• W2594133760 hasAuthorship W2594133760A5049711954 @default.
• W2594133760 hasAuthorship W2594133760A5063422967 @default.
• W2594133760 hasAuthorship W2594133760A5064631593 @default.
• W2594133760 hasAuthorship W2594133760A5069449708 @default.
• W2594133760 hasAuthorship W2594133760A5077388722 @default.
• W2594133760 hasAuthorship W2594133760A5081769123 @default.
• W2594133760 hasAuthorship W2594133760A5084124427 @default.
• W2594133760 hasAuthorship W2594133760A5086005303 @default.
• W2594133760 hasAuthorship W2594133760A5086077649 @default.
• W2594133760 hasAuthorship W2594133760A5089163384 @default.
• W2594133760 hasConcept C126322002 @default.
• W2594133760 hasConcept C143998085 @default.
• W2594133760 hasConcept C2776063141 @default.
• W2594133760 hasConcept C2776364478 @default.
• W2594133760 hasConcept C2777478702 @default.
• W2594133760 hasConcept C2780401358 @default.
• W2594133760 hasConcept C2781119759 @default.
• W2594133760 hasConcept C2908647359 @default.
• W2594133760 hasConcept C71924100 @default.
• W2594133760 hasConcept C99454951 @default.
• W2594133760 hasConceptScore W2594133760C126322002 @default.
• W2594133760 hasConceptScore W2594133760C143998085 @default.
• W2594133760 hasConceptScore W2594133760C2776063141 @default.
• W2594133760 hasConceptScore W2594133760C2776364478 @default.
• W2594133760 hasConceptScore W2594133760C2777478702 @default.
• W2594133760 hasConceptScore W2594133760C2780401358 @default.
• W2594133760 hasConceptScore W2594133760C2781119759 @default.
• W2594133760 hasConceptScore W2594133760C2908647359 @default.
• W2594133760 hasConceptScore W2594133760C71924100 @default.
• W2594133760 hasConceptScore W2594133760C99454951 @default.
• W2594133760 hasIssue "22" @default.
• W2594133760 hasLocation W25941337601 @default.
• W2594133760 hasOpenAccess W2594133760 @default.
• W2594133760 hasPrimaryLocation W25941337601 @default.
• W2594133760 hasRelatedWork W14748329 @default.
• W2594133760 hasRelatedWork W1699374300 @default.
• W2594133760 hasRelatedWork W1988784378 @default.
• W2594133760 hasRelatedWork W1996748901 @default.
• W2594133760 hasRelatedWork W2010232494 @default.
• W2594133760 hasRelatedWork W2192430028 @default.
• W2594133760 hasRelatedWork W2330049167 @default.
• W2594133760 hasRelatedWork W3134875278 @default.
• W2594133760 hasRelatedWork W3217566318 @default.
• W2594133760 hasRelatedWork W2309095625 @default.
• W2594133760 hasVolume "128" @default.
• W2594133760 isParatext "false" @default.
• W2594133760 isRetracted "false" @default.
• W2594133760 magId "2594133760" @default.
• W2594133760 workType "article" @default.